Two Stakeholders You Can’t Ignore

Interview with Tioga CEO Mike Dineen

Listen to the Episode

0:000:00

Listen to the Episode

0:000:00

About the Guest

Mike Dineen has 30 years of experience in leading and scaling innovative medical device startups, and is co-inventor on more than 65 patents. His track record encompasses leadership roles at Kalila Medical (acquired by Abbott and later divested to Terumo), Maya Medical (acquired by Covidien), and Aspire Medical (acquired by Philips/Respironics). Today, he’s the co-founder and CEO of Tioga Cardiovascular, a Shifamed portfolio company.

Interview Summary

Mike Dineen, co-founder and CEO of Tioga Cardiovascular, started out as a pre-med student but shifted directions halfway through his undergrad after being drawn to the idea of combining medicine with business. After earning a BS in Biology and an MBA from Santa Clara University, he started in pharmaceutical sales at the Upjohn Company (now Pfizer). It wasn’t long, though, before his passion for innovation pulled him into the medical devices world, starting at Devices for Vascular Interventions (DVI), which ultimately exited to Guidant. 

His next stop was Target Therapeutics, where he witnessed the company’s acquisition by Boston Scientific, giving him a front-row seat to how startups scale and succeed. Inspired, he co-founded Radiant Medical, a startup focused on therapeutic hypothermia, followed by Aspire Medical, which developed a minimally invasive device for sleep apnea. Despite the financial crisis at the time, Aspire was acquired by Philips/Respironics.

Along the way, he met prolific entrepreneur Amr Salahieh, President and CEO of Shifamed, and joined two of Shifamed's portfolio companies: Maya Medical and later Kalila Medical, where he served as CEO. After taking a well-earned break to focus on family and explore van life, Mike co-founded Tioga Cardiovascular, another Shifamed portfolio company. 

The Tioga Cardiovascular team is developing a minimally invasive device to treat mitral regurgitation (MR), a common heart valve condition where blood leaks backward into the heart, often causing heart failure or shortness of breath. Current repair devices, like MitraClip and Pascal, don’t work for every patient and often leave residual issues. To fully treat the condition, physicians need a transcatheter mitral valve replacement (TMVR) option. 

TMVR is a promising technology that bypasses the need for open-heart surgery for patients with MR but as of today, it’s in its infancy. Most TMVR devices have high screen failure rate, where 80-90% of patients are excluded because the devices don't fit. Tioga Cardiovascular aims to solve this by creating a better delivery system and a shorter, more compact valve, making treatment accessible to more patients, and saving them from undergoing an open-heart surgery. 

In September 2024, Tioga completed its first-in-human procedure and has since performed three successful cases, with more patients currently being screened. Tioga plans to continue to gain early clinical experience in the upcoming year with sites outside the U.S.

Key Learnings From Mike’s Experience

  • Start with identifying real clinical needs by talking directly to physicians. Understand their pain points, the number of patients impacted, and the clinical significance of the issue. Work closely with key opinion leaders (KOLs) in your field who can provide deep insights into care gaps and guide you toward viable solutions. While doing this, ensure your device aligns with what strategics are looking for—or be prepared to take it further on your own.


  • Get a functional prototype into pre-clinical testing as soon as possible. Don’t over-refine—early testing reveals critical insights you won’t get from theory alone. Choose clinical sites that are credible, accepted by physicians, and see a high volume of relevant patients. Back your team with strong CRO support for navigating site-specific requirements.


  • For capital, seek out firms in your field that are interested in early-stage deals, especially Series A. Present a clear, compelling story that outlines a feasible path to an exit within their typical timeline. Similarly, engage with strategics early and treat them as customers. Take the time to understand their pain points and key initiatives, even as those priorities evolve over time.

Prioritize Insider Insights

Not all great ideas make great companies. Mike, a seasoned entrepreneur with multiple successful exits, boils it down to one thing: clinical need. 

“I always go back to the fundamentals: clinical needs,” he says. The best way to assess this isn’t necessarily by reading reports or studies; it’s by talking to physicians. It starts with understanding their pain points, the number of patients affected, and the severity of the issue—things like morbidity or mortality. “Do they need a better tool? That’s where it starts,” Mike says. 

Mike emphasizes that physicians—not marketers—define the market. “If you sit down with physicians, you’ll see how they segment patients by disease state, anatomy, and other factors. That shapes how early-stage device markets are defined,” Mike shares.

However, “Not every physician will give you deep insights,” he notes. It’s important to work with the right physicians in your chosen vertical, who can help you understand what’s missing in the field and where new technologies could make a real difference.

To bring a solution to market, he advises spending time in the trenches. “You’ve got to really get into the brain of the users,” he says. Watch procedures, attend conferences, and have meaningful conversations with physicians. “See who’s speaking on the podium, start a relationship, or at least a conversation.”

The second layer to consider is strategic fit. Some ideas may solve a clinical need but don’t align with what strategics are looking for. That’s not necessarily a dealbreaker, but, as Mike explains, “You need to know that upfront because it might mean you’ll have to take the project further on your own.”

Interventional cardiology, for instance, is a proven space where physicians are proactive in adopting new technologies, and strategics are often seeking innovative solutions. Other fields, like sleep apnea, present challenges because patient care is fragmented—ENT surgeons see some patients, and pulmonologists see others. “No one really owns the patient,” Mike notes, which complicates market development.

Reduce Complexity and Test Early

One of the toughest challenges for medtech startups is iterating early on, especially with limited capital and resources. “The most important thing is to get a prototype working in an animal model as soon as possible,” Mike explains. It’s tempting to refine endlessly, but pushing to create something functional for pre-clinical testing is critical.

Simplifying complexity is no small task. Engineers often get caught up in creating intricate designs or running endless iterations in SolidWorks. It takes real talent to strip that down into something functional and streamlined. “We spent a good three years going back and forth before we had a valve that worked reliably in a pre-clinical model,” Mike shares. The complexity we started with was a far cry from the streamlined solution we eventually brought to the clinic. Throughout this time we’ve reduced the complexity dramatically. “Push for pre-clinical testing early, even if it’s uncomfortable,” Mike advises, “because it actually drives questions that you wouldn't otherwise be thinking about.”

When it comes to clinical work, credibility is key. Tioga is running trials in Paraguay and the Republic of Georgia. As a mitral valve company, the team needed clinical centers that physicians respected, handled high patient volumes, and could provide long-term care. “TMVR is an implant solution, and implanting the valve is just the beginning,” Mike says. “These patients become your responsibility for life.” Tioga ensures follow-up care, medication management, and overall patient oversight to uphold this commitment.

Equally important is having strong CRO support. “Even if you have a great regulatory advisor, you’ll still need local knowledge to navigate site-specific requirements and processes,” Mike advises.

These strategies worked well for Mike and Tioga, but your niche might have its own unique requirements. For example, the choice of clinical sites could vary depending on the patient population and technology you’re working with. That said, key principles like reducing complexity, engaging credible sites (especially if you’re working internationally), building strong local support, and pushing for early testing, hold true across most scenarios.

Solve the Problem for All of Your Stakeholders: Physicians, Investors, and Strategics

Fundraising in medtech is tougher than it was 20 years ago. “Many traditional VCs have pivoted to tech,” Mike explains, leaving a smaller slice of the funding pie for medtech startups. While the overall investment dollars are still significant, the landscape has become more challenging.

Tioga has raised around $90 million so far, with their Series C completed in 2023. Mike credits much of this success to being part of the Shifamed ecosystem. “That’s my first piece of advice—make sure you’re in a good ecosystem. It’s incredibly helpful,” he says. At Shifamed, resources like finance, accounting, and HR are centralized and standardized, sparing startups the need to build these functions from scratch. “Plus, we’re all close to one another. If I have a question, I can just walk across the street and talk to someone. All the CEOs get together and we talk about what's working for the companies, where they are, what the key strategic messages are,” Mike adds.

Whether you’re part of an ecosystem or operating independently, raising outside capital early is critical. Target firms that are interested in early-stage deals, especially Series A, and engage with them at the right time. These firms often won’t jump in at Series B or C, so connecting early is key. Mike stresses the importance of having a clear, compelling story that outlines a realistic path to an exit within their typical horizon with measurable milestones.

The same principle applies to engaging with potential acquirers. Mike points out, “Just like physicians are customers, strategics are also our customers, too.” Building relationships with large multi-nationals early helps you understand their priorities, pain points, and future direction, even as these evolve. This perspective is crucial for shaping your product and positioning your company for an eventual exit.

Some founders hesitate to approach strategics too soon, fearing their IP might be stolen. But in medtech, Mike believes this concern is overblown. While patents are important for protecting your invention and ensuring freedom to operate, they shouldn’t take precedence over solving the core problem. “If you solve the problem, the IP usually works itself out,” Mike says. You may need to make adjustments later, but that’s far more manageable once you’ve developed a working solution. “It’s easy to get caught up in the idea of being an inventor with lots of patents, but patents don’t matter if your solution doesn’t work,” Mike adds. In short, IP is important, but it’s secondary to creating a functional, impactful product. The real focus should always be on solving the problem.

Check Out the Podcast →

Sponsors

  • FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.

  • Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.

Don’t Forget

Interested in advertising with us?
Get in Touch →

Want to learn from more startup CEOs?
Check Out the Archive →

Forwarded this email?
Join for Free →

Who's Scott Nelson again?
See His Bio →

Transcript

0:00:00 [upbeat music] The amount of pressure and the ups and downs are so dramatic that it's extremely difficult on a day-to-day basis to kind of maintain your [laughs] sanity sometimes.

0:00:11 [laughs] You know, I think this is true for any CEO, right? Because you have financing woes, you have patient woes, you have, uh, patient enrollment wo- wo-woes.

0:00:18 You have a lot of different things that you're trying to manage. And I think the-- w- what you start to realize or what I've really started to realize is that you've got to focus on a process.

0:00:26 And more than anything else, sometimes when you, when you get overly consumed about the outcome, whatever, from two years, three years from now, it becomes overwhelming.

0:00:36 You gotta divide your, your year into months and then months into weeks and then days, and really just focus on what you're gonna do, uh, that's right in front of you.

0:00:45 Sitting down the night before and really deciding what you're gonna do the following day, and don't even do anything at the time. Just really try to focus and try to get into a l- little bit of a zen mode and- Hmm...

0:00:55 think about what are the most impactful things you can do in the next day. That's how you're gonna eventually move the needle forward.

0:01:01 Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.

0:01:08 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey, everyone. It's Scott.

0:01:22 In this episode of MedSider, I sat down with Mike Dineen, who has over 30 years of experience in leading and scaling innovative medical device startups and is co-inventor on more than 65 patents.

0:01:30 His track record encompasses leadership roles at Kalea Medical, which was acquired by Abbott and later divested to Terumo, Myo Medical, which was acquired by Covidien, and Aspire Medical, acquired by Philips Respironics.

0:01:41 Today, Mike is the co-founder and CEO of Tioga Cardiovascular, a SheevaMed portfolio company. Here are a few of the key things that we discussed in this conversation.

0:01:48 First, start with identifying real clinical needs by talking directly to physicians. Understand their pain points, the number of patients impacted, and the clinical significance of the issue.

0:01:58 Work closely with key opinion leaders in your field who can provide deep insights into care gaps and guide you toward viable solutions.

0:02:04 While doing this, ensure your device aligns with what strategics are looking for or prepare to take your startup further on your own. Second, get a functional prototype into preclinical testing as soon as possible.

0:02:13 Don't over-refine, as early testing reveals critical insights you won't get from theory alone. Choose clinical sites that are credible, accepted by physicians, and see a high volume of relevant patients.

0:02:23 Back your team with strong CRO support for navigating site-specific requirements. And third, for capital, seek out firms in your field that are interested in early-stage deals, especially Series A.

0:02:32 Present a clear, compelling story that outlines a feasible path to an exit within their typical timeline, which is six to ten years. On a similar note, engage with strategics early and treat them as customers.

0:02:42 Take the time to understand their pain points and key initiatives, even as those priorities evolve over time.

0:02:47 All right, before we dive into this episode, I'm pumped to share that volume seven of MedSider Mentors is now live.

0:02:52 This latest edition highlights key takeaways from recent MedSider interviews with incredible entrepreneurs like Bill Hunter, CEO of Canary Medical, Brian Lord, CEO of Pristine Surgical, Don Crawford, co-founder of Saphion and current CEO of Corvista Health, and other proven med tech founders and CEOs.

0:03:07 Look, we get it. Keeping up with every MedSider interview isn't easy. That's why we created MedSider Mentors.

0:03:12 These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format. To check the latest volume out, head over to medsideradio.com/mentors.

0:03:25 Premium members get free access to all past and future volumes, plus a treasure trove of other resources. If you're not a premium member yet, you should definitely consider signing up.

0:03:33 We recently revamped MedSider with swanky new features, especially for our premium members. In addition to every volume of MedSider Mentors, you'll get full access to our entire interview library dating back to 2010.

0:03:44 You'll also get MedSider Playbooks, curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more.

0:03:52 And if you're fundraising, don't miss our exclusive investor database, featuring over 750 life science VCs, family offices, and angels. We've even created three custom packages to help you with your next fundraise.

0:04:03 Learn more about MedSider Mentors and our premium memberships by visiting medsideradio.com/mentors. All right, without further ado, let's dive into the interview.

0:04:11 [upbeat music] All right, Mike, welcome to MedSider Radio. I'm really looking forward to this discussion. It's been a, a, a while coming, so yeah, this should be a fun one. Likewise, yeah. Looking forward.

0:04:23 Great to be here. Yeah. Uh, so I recorded a, a very short bio at the outset of this episode, but let's start there. You've got, you've got a laundry list of experiences, right?

0:04:30 That are quite, uh, impressive from early in your career at Strategics, then in just a, a number of different startups that you've been with over the past 15 to 20 years now, I think.

0:04:37 With that said, give us like a two-minute elevator pitch on your background leading up to Tioga. Yeah.

0:04:42 It re- if I go back, way, way back to college, I was, uh, actually pre-med in college, and I thought I was gonna go to medical school.

0:04:49 I've always really been interested in medicine, and then abou- probably about halfway through college, I decided that medical school wasn't for me.

0:04:55 I didn't feel like going through ye- years and years of a residency in medical school.

0:04:58 I had this semi-brilliant idea of somehow mixing business with medicine, in that I figured that there was a lot of people with business backgrounds who wouldn't understand medicine and-or science.

0:05:08 So I decided, I didn't know what that meant at the time, but fast-forward to when I graduated, I, I actually took a job in pharmaceutical sales.

0:05:15 So that was my first job out of college, and that was at a ve- very large pharmaceutical company, which was a great training background, et cetera, f- not only from a sales standpoint, but also just understanding medicine and different specialties and everything.

0:05:28 My first, uh, job in med tech really came in my late 20s, actually, when I was-- I, I went to work for a company called DVI, which is one of John Simpson's companies. John Simpson formed A-ACS, as you probably know.

0:05:40 Then he went on to form, uh, DVI, which is an atherectomy company, and that's really where I got really interested in interventional cardiology.

0:05:46 And that actually set my career off more than anything else in the world, uh, 'cause it was working with just really fantastic people, and it, and it's literally one of the most important things for when you're starting a career is making sure that you're working with really good people.

0:05:59 Hmm. And then from there-- and I was in a marketing role. So I, I went from the sales role to the marketing role.

0:06:05 And then from there I went to a company called Target Therapeutics, which was one of the early neurointerventional companies right before the time it was acquired by Boston Scientific.

0:06:14 So I got to live through the BSC acquisition, and right after that one of our...

0:06:19 I was introduced to a venture capitalist at 3 Arch Partners, which at the time was one of the big venture, med tech venture groups in the, really in the country. And we started a company called Radiant Medical.

0:06:31 That was a, one of the cooling companies, one of the therapeutic hypothermia companies. So what... And this was philosophically, which also very much shaped my career.

0:06:40 The VC at the time said that what they like to do is put together somebody with a business or marketing background together with somebody with a technical background and have them come up with a business.

0:06:49 And it actually worked out really well because- Mm-hmm...

0:06:51 I worked with an engineer very closely, and we tried to figure out market needs and clinical needs, and we came up with a bunch of really interesting things, which unfortunately, whi- which got funded, but then the trials didn't necessarily pan out.

0:07:03 And so that lasted a few years, and I came back to the venture firm a few years later, also as an EIR at this time, as an entrepreneur-in-residence, and started another company in sleep apnea, and we sold that to, to Philips.

0:07:16 Unfortunately, we, that was right around the time of the global financial crisis, so we actually ran out of funds, and we actually had some technical problems.

0:07:23 And then I spent some time in an interventional, uh, stroke company marketing side, and then I met Amr back in 2011.

0:07:31 And this is really where things, I think, get interesting because Amr was a prolific entrepreneur, started a number of different companies, and he was starting MyoMedical, which was a renal denervation company.

0:07:43 Again, as I mentioned to you earlier, it was out of his house. Mm-hmm. And so he needed help with just a lots of odds and ends. And so in an early-stage company, you just have to be willing to, to do whatever.

0:07:51 And so my job was a little bit of clinical, a little bit of marketing. I served as a subject matter expert on some of the design reviews, [laughs] et cetera. And just getting stuff done.

0:08:01 And that company was acquired by Covidien back before Covidien was part of Medtronic.

0:08:06 And, uh, so I was at Covidien for a while, for only about six months, and then Amr asked me to come back and run Calila Medical which was one of the other early sheath of med companies.

0:08:16 And that was a steerable sheath that competed with the St. Jude Agilis, which is now Abbott Agilis of course. And, uh, so we sold that to, uh, Abbott Labs, uh, in 2016.

0:08:28 And then right after the acquisition closed, about literally a month and a half later, Abbott acquired St. Jude Medical. It was a really big acquisition at the time. It was like a $25 bil- billion acquisition.

0:08:40 But the Federal Trade Commission made Abbott divest Calila. So we were di- subsequently divested to Terumo Medical, so I ended up at Terumo. Mm-hmm.

0:08:49 And we were still working through milestones, 'cause the deal had about 50% milestones. So we worked through all the milestones, got the milestones done. I left, I left Terumo, took a bit of time off.

0:09:01 Actually bought a van, built out a van, traveled around with the kids.

0:09:04 [laughs] Did a little bit of van life, and then took, came back and started looking at new companies, what then we were gonna start, the next generation of sheath of med companies.

0:09:12 And this was like early 2018 at this time.

0:09:16 And so we looked at a number of different things before we got really excited about the mitral valve space, and that's the project that ultimately led to Tioga and where we are today. Yeah.

0:09:26 Is T- T- Tioga, isn't that like a van? It, like, I've seen like campers like with Tioga. [laughs] Is that like a brand? Is there any, like, backstory to that at all? Yeah.

0:09:34 So Tioga, so we were named after Tioga Pass in Yosemite. Oh. So it's the highest paved road in California. It closes down every year, like in November because of snow.

0:09:44 And so w- a couple of our early co-founders were, were climbers and doing some ice climbing up in Tioga Pass. And they, they came back and said, "Why, why don't we make a Tioga Medical?"

0:09:54 And, and actually it's, the Tioga is actually the name of, it's an Iroquois name- Oh... from Upstate New York, and it means something about rivers or flows or something like that.

0:10:03 So that's where the, where it comes from. That's cool. That, and I'm l- looking forward to learning a little bit more about the journey over the past, I guess half decade now with Tioga, I think, right?

0:10:11 'Cause you I think maybe officially started it in, in '19, maybe were tinkering before then. But, yeah, that's a, that's a, that's a fun background.

0:10:16 But on that note, before we get into, to Luna, learning a little bit more about Luna, I'm hoping that at the very least you got paid twice on those milestones, right?

0:10:23 Through the integration of, with, with- We didn't get paid twice. Yeah. We just got paid, we got paid completely. Okay. [laughs] So that's more importantly, yeah. Yeah.

0:10:30 Two, two, two swings maybe at the plate there- Yeah... with those milestones. But, but joking aside, tell us a little bit about Luna. Yeah.

0:10:35 And maybe start with the big problem you're trying to solve, and then maybe how your system differentiates from others. Yeah. So mitral regurgitation is the largest heart valve problem. There's four valves in the heart.

0:10:46 The most famous one now of course is the aortic valve because Edwards has built its entire business around treating the aortic stenosis, which is the valve right next to the mitral valve.

0:10:57 Mitral regurgitation occurs, uh, when you have obviously a leak of the blood going backwards into the left atrium, and it, and it presents with heart failure or shortness of breath.

0:11:06 And, and again, it's the biggest heart valve problem that ex- exists in the world today.

0:11:13 And right now from an interventional standpoint, the only thing that's really out there is TEER, transcatheter edge-to-edge repair, which is MitraClip and Pascal by, MitraClip by Abbott and Pascal by Edwards, which is a repair device.

0:11:26 The problem with a lot of the repair devices is that there's certain anatomies that they can't treat or that they treat suboptimally, meaning that they leave a lot of, uh, residual MR behind.

0:11:36 Physicians really want a transcatheter mitral valve replacement option to be able to treat s- these patients and to treat the MR. So that's where a TMVR device comes in.

0:11:46 Now, where we're really differentiated is that all the other TMVR devices, and there's a bunch that are in clinical evaluation, they have a really high screen failure rate, meaning that when a patient is referred to the company to look at whether or not the valve will fit in that patient, they usually go through the process and very often- They are denied treatment.

0:12:09 And actually it happens ridiculously, like a very, very high rate. So for some of the major competitors, 80 to 90% of the patients are excluded from treatment before- Mm... you know, uh, at is... at the screening level.

0:12:24 So a big part of what we're trying to treat is, or trying to address rather, is the screen failure rate, and try to- Mm... lower that screen failure rate.

0:12:33 The way we've done that is by making, uh, a better delivery system, number one, and number two is a more compact...

0:12:39 And there's some other things as well, but more than anything else, those are the two p- two main design components that have led to where we are today as a company.

0:12:47 And that, and that high screening rate, which is like absurdly high, I had no idea it was that high. Yeah. It...

0:12:51 That, that's largely due to just, like the sort of the technical constraints of existing therapies, existing devices? Yeah.

0:12:56 If you look at one of the major competitive valves from, say, Medtronic, it's a very tall valve and it occupies the entire mitral annulus.

0:13:05 So it's so big that it actually blocks what's called the left ventricular outflow tract, which is where the blood leaves the heart. It's the area just below the aortic valve.

0:13:14 And really what the company and all the companies will do is they'll take a patient CAT scan and then they'll put a virtual valve into that patient's anatomy and make sure that there's adequate room for it.

0:13:27 And, and if there's not, they won't treat the patient. So you actually do a virtual implantation of the valve before you do the real one, and that's really where the screen failure, uh, rate occurs the most often.

0:13:38 Got it. Got it. I'm on the website right now, tiogacardiovascular.com, just as it sounds, right? T-I-O-G-A cardiovascular.com. We'll link to it in the full write-up on MedSider, uh- Yeah...

0:13:47 as well as Mike's LinkedIn profile. But give us a sense for where the company is at. I, I know you recently, uh, announced some first in human cases.

0:13:54 We're recording this in late '24, but I think that was maybe a couple months ago or something like that. But give us a sense- Yeah... of where you're at right now in terms of stage. Yeah.

0:14:00 So we did our first in human in September, and we've done now three cases, and we're screening more cases. All the cases have gone really well from an acute standpoint.

0:14:08 So we just literally just entered the clinic, and we're gonna be doing more cases in 2025. Got it. Cool. Very good. I'm sure with some sights on some sort of IDE trial at some point in the future, correct? Yeah.

0:14:20 So we're starting, like most companies, we're starting outside the US, so we have a number of sites outside the US. And then next year

0:14:28 we'll be-- we're planning to submit a, an EFS IDE to the FDA, and then start- starting treating patients in, in the US after that. Got it. Very cool. Uh, it'll be fun to watch the progress.

0:14:38 Exciting stage for Tioga, especially considering there's been a lengthy development process to date.

0:14:42 With that said, let's spend the next maybe 20, 30 minutes or so going through some, I like to call these just different cross-functional kind of topics, if you will, right, that every startup or ambitious founder that's listening to this is gonna have to probably address at some point if they're gonna expect their venture to see some light of day.

0:14:56 First one on the docket is you went through kind of the lengthy list of various [laughs] companies that you've been with, right? That are not just specific to cardiovascular, right?

0:15:03 Sleep apnea, cooling or hypotherm- you've spent some time [laughs] in the hypothermia space, which is quite interesting. And so you've seen a lot of ideas, right?

0:15:10 And e- I think maybe even you mentioned when you circled back around after taking some time off at, at, uh, circled back around with, with Amare, you probably evaluated a number of different concepts.

0:15:17 So when you think about, like where to go, where- how to choose, right?

0:15:21 How to determine whether or not an idea is even worth, even worth pursuing, are there a few things that kinda come to mind that would help another, another founder maybe that's never-- doesn't have as many swings at the plate as you really hone in on, on something that might actually work?

0:15:33 Yeah. I, I always go back to fundamentals, which are clinical needs, right? And, and if there's a marketing clinical need.

0:15:38 And, and the way to, to assess this, in my opinion, is not necessarily to read a bunch of things or look at reports or anything like that. It's actually to go out and talk to physicians. Mm.

0:15:49 Where are the pain points that they're having? Do they see a lot of these patients? Are there... Is there a lot of morbidity and/or mortality associated with this? Do they need a better tool? So that's where it starts.

0:16:00 So it's making sure that you actually have the right set of KOLs. And again, like this is assuming obviously that you're already moving into a...

0:16:08 You, you already have a vertical identified, like interventional cardiology.

0:16:11 And then from there, I think you have to take a look at the strategic space and making sure that what you're working on is gonna ultimately fit with the strategic.

0:16:22 Now, there are more disruptive things that actually have a great clinical need, but they don't necessarily fit with the strategic, and that's okay.

0:16:31 It just, you have to know about that, 'cause it may mean that you have to take it longer and, and really get into commercialization more, more directly into commercialization, as opposed to certain areas of, of, of...

0:16:44 Well, a lot, a lot of interventional cardiology is like this, for example.

0:16:46 There are-- there's a number of things in structural, whether they be mitral or anything outside of structural, where strategics are looking for better solutions that can treat more patients, that are easier to use, that have better outcomes, et cetera.

0:16:59 So you wanna make sure that, I think, that it fits both of those things. And then the, the final thing actually, and this actually may, may actually go first, is just picking the vertical.

0:17:08 When you get outside of certain verticals, things get a little bit harder. I think- Mm... I think that... I still think that interventional cardiology is a better vertical to operate in.

0:17:17 And, and, and really all of cardiology is a better vertical, just because of the physicians, whether they be an interventionalist or, or electrophysiologist, are all looking to adopt new technologies, and they're open to new technologies.

0:17:30 Other spaces that I've worked in have really big clinical needs, but they're harder to access. So I think sleep apnea is a really good example.

0:17:38 That sleep apnea company I did 15 years ago, 15 plus years ago, is that there's the ENT surgeon who sees some of these patients, but then there's a pulmonologist that sees patients, and then there's really no one that really owns the patients- Mm...

0:17:52 that, that, you know... And so it becomes very difficult from a market development standpoint. And again, it doesn't mean that you, you don't pursue a project like that.

0:18:01 It's just you have to really go into it with eyes wide open, I think. Yeah. That, that's a really interesting point. I wanna circle back around to the, the, the first thing that you mentioned as well. But the...

0:18:09 that kind of understanding sort of the workflow, if you will, how patients come into an, a certain kind of pathway and how they're referred.

0:18:15 Do you think that, like- O- oftentimes that's the nature of that specialist, or it's just this a, a sym- like a sort of more of a symptom of this is how kind of patients have navigated the pathway for 20 or 30 years, and it just remains the same.

0:18:28 Or you think it's more, like car- you mentioned interventional cardiology, like a lot of cardiologists, as we both know, they're just aggressive, right? Yeah.

0:18:33 Not only do they own the patient, but like they're aggressive about adopting, adopting new therapies. So do you think it's a mix of both or one or the other?

0:18:39 So you're talking about whether or not it's patient-driven versus physician-driven? Yeah. Correct. Yeah. Yeah. Yep. I, I think in interventional car- cardiology it's not necessarily patient-driven.

0:18:48 I think these are all patients that for one form or another are already being seen by cardiology.

0:18:54 I, I don't think there's a lot of patients that are trying to seek out a better left atrial appendage closure device or something like that. They may... Some of them may.

0:19:02 They, they may get to the point where they're deciding, "I don't wanna take Coumadin or anticoagulants anymore, and therefore I wanna, I wanna see what I can do around this."

0:19:10 I think that's probably some of it, but it's probably more because the cardiologists are more likely to offer those therapies. Mm.

0:19:16 Now, if you're talking about something like sleep apnea, then it's gonna be m- much more patient-driven, right? Because that's really an elective procedure.

0:19:25 Most of these procedures are elective, but some procedures are more [laughs] elective than other procedures. Yeah.

0:19:29 And I think that's where it gets a little bit stickier is when you're really having to reach into patient populations and get them to drive it. And we see this with a lot of less traditional therapeutic areas.

0:19:41 Not so much things that chief med companies are working on, but non-chief med companies are working on.

0:19:46 I can think of a few, I don't wanna necessarily mention them, but they have tackier or stickier patient flow dynamics, because there's not one specialty that is just seeing all these things, or the specialty that is seeing all these patients is not the one that's gonna do the implanting, and that's hard.

0:20:03 Yeah.

0:20:03 That's a really, that's a really good point, and something that I think probably a lot of folks that haven't been around as long as you have or d- have, have done as many startups as you have, aren't thinking about that friction, that kind of- Yeah...

0:20:13 commercial friction early on, so that's a really good point. You mentioned the, the first answer in what I like to c- consider getting in the mix, whether you call it VOC or just engaging directly, right?

0:20:21 Like, with the end users.

0:20:23 Do you think that stems from, like, some of your commercial background early on, just knowing how truly valuable that is just to have real, like, conver- like discussions, conversations with interventional, interventionalists or name your specialty?

0:20:34 Yeah. I, I, I think that's just where I've come from. Yeah. I've come from more of a commercial background and I, and I've always turned to physicians.

0:20:42 And again, you wanna make sure you're turning to the right physicians, 'cause not every physician is gonna give you deep insights.

0:20:48 But the one of the things that's great about cardiology is that it's really easy just to reach out to somebody that you don't even know.

0:20:53 Yeah, there's a whole group of people that know people that you know, but then there's other people that you don't have any connection to, but you can find their email, reach out to them, and they're like, "Oh yeah, I'll meet y- I'll meet you at TCT," and then, you start a relationship.

0:21:05 So it's, it's really easy to see who's talking on the podium and then start a relationship with them or at least a conversation with them afterwards.

0:21:14 But yeah, I think it actually has to come from a clinical need and, and- Mm-hmm... and has to come based off of watching a procedure, watching a disease state, et cetera.

0:21:25 It, it all comes down to when I was at 3Arch, which was Tom Fogarty's venture capital firm, he talked about... It, it was, I always thought it was interesting.

0:21:33 He said that, he always said, he, he said a number of things that really stuck with me. One of the things when I was in marketing that he us- used to say is he said, "People in marketing don't segment the market.

0:21:42 Physicians segment the market."

0:21:44 And, and I thought that was a really interesting way of saying it because if you really sit down with a physician and you can understand the buckets of patients that they're thinking about, that's ultimately how m- for early-stage device technologies especially, how the market gets segmented- Mm-hmm...

0:21:59 by disease state and by anatomy and by this and, and, and everything. So I, I think I've retained a mixture of the commercial and clinical- Mm... uh, background, if that makes any sense.

0:22:11 And I think it's really hard, 'cause a lot of people that come from a marketing background don't necessarily like to get super technical when it comes to medical issues.

0:22:20 They're, they tend to be more promotional or they've worked on sales tools or something like that, which is all well and good, but if you're really gonna be doing this upstream stuff and starting companies, you've got to really sit down and get into the brain of the users and find out where the pain points are.

0:22:36 And the only way to do that is to really understand what they're doing, spend time in the lab, go to meetings, talk to people. Yeah, no doubt. Like the best marketers that I've ever known- Yeah...

0:22:45 can, can hold their own, right, in an R&D conversation, right? Absolutely. 'Cause they just know, they know the space, they know the technical constraints of developing a certain product to, to meet a certain need.

0:22:53 That's a really good point. Let's transition to whether you wanna frame this up to the early days of Tioga or just give us an example. I'll let you take it from here.

0:22:59 But let's say you've identified a, a need or an area to tackle. You've got a, you've got a concept that you think is worth pursuing.

0:23:05 Some of the hardest work that, in my opinion, is, like, trying to iterate early on when there's not a lot of capital to play with and l- resources are pretty, pretty lean.

0:23:13 And so I'm, I'm sure, like Luna as an example, right? It looks a lot different now that it's in patients than it did very early on.

0:23:18 And what are, like, your best tips for other, whether it's a, a physician that wants to pursue an idea or another engineer that wants to do a startup, like, what are the kind of the keys to success to, like, quickly iterating with limited resources in those early days?

0:23:29 I think the most important thing is to try to get a prototype working in an animal model as soon as possible. And a lot of times, sometimes there'll be some resistance, "Oh, we're not ready.

0:23:39 We need more time," et cetera. But, like, literally forcing yourself to reduce it to something that will work in a model, in a preclinical model, is really important. Mm. And,

0:23:49 um, it took us a lot to get to where we are today. We went through probably a good three years of back and forth to get to a funct- a, a valve that we knew we could land in a preclinical model.

0:24:04 It did not happen overnight at all. And the complexity that we started out with versus where we are today, we have reduced the complexity dramatically over the last- Mm... uh, really three, two to three years.

0:24:18 So I, I think you gotta push it into an, into a preclinical model as soon as possible, and then I think you have to really- Make sure you have an engineer and an engineering team that's willing to throw out complexity.

0:24:31 There's a lot of engineers, and again, I don't wanna speak negatively about engineers, but it's really easy

0:24:38 to make something really complicated in some ways 'cause everyone gets excited about solid works and doing- Mm-hmm... a bunch of iterations of things.

0:24:47 It takes a real talent to make something, to, to take that complexity and reduce it into something that's simpler. Mm-hmm. And so I think it's really applied to both of those things. Mm-hmm.

0:24:57 It's I- I would say pre-clinical models as well as reducing complexity. [upbeat music] Hey everyone, let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO.

0:25:08 We're developing next generation intravascular lithotripsy systems, or IVL for short, to tackle complex calcific disease. The IVL market is valued at over $10 billion, but there's currently only one major player.

0:25:19 In early 2023, we opened up an investment opportunity to our community, and within a month we secured close to $10 million.

0:25:27 Then in early '24, we closed an oversubscribed $19 million round in just a few weeks, bringing the total investment into Fast Wave to over $40 million. Corporate interest in the IVL space is growing too.

0:25:37 The $900 million acquisition of Bolt Medical by Boston Scientific, and then J&J's $13 billion acquisition of Shockwave Medical signals a lot of attention towards emerging IVL startups like Fast Wave, and we're making some serious progress.

0:25:51 Fast Wave recently received its seventh patent for our differentiated laser IVL platform for coronary applications.

0:25:57 On the clinical side, last year we completed the first inhuman study of our advanced electric IVL system with some pretty compelling results.

0:26:04 Next up, in 2025 we have IDE trials planned for both our peripheral and coronary IVL platforms.

0:26:10 So if you're interested in investing in the fast-growing IVL market, sign up for our investor wait list at fastwavemedical.com/invest. Again, that's fastwavemedical.com/invest. Now let's get back to the conversation.

0:26:22 [upbeat music] Yeah, that, that you mentioned when you're touching on, on pre-clinical models, there's always this hesita- hesitancy of are we really ready? Are we... You know, there's like a- Yeah...

0:26:31 a level of discomfort there, and I, I'm, I'm nodding in, in agreement. We're recording this on video. I'm nodding in agreement 'cause, like, I, I see the same things, right?

0:26:38 There's always this, "Oh, we're not quite ready. We need another week," or, "We need another month"- Yeah... or whatever. And are you of the opinion that if it's good enough, just almost set a date just to- Yeah...

0:26:46 force-- It's almost a forcing function, right? For everyone- Yeah... to align around to get into a, a pretty significant milestone, like a pre-clinical lab. Yeah.

0:26:53 I think there, there was some, there was some friction between a few [laughs] of us early on, very early on about doing just that.

0:27:00 Like, I was like, "Let's get into a, into a study as soon as possible," and some of the R&D folks were like, "Every time we do a study it sets us back two weeks 'cause we have to get ready for the study."

0:27:09 I'm like [laughs] "This is what we're doing." Yeah. And so we had a lot of those kind of conversations, and eventually we got into a good cadence. But- Yeah... I, I, I think you gotta push yourself to it- Mm-hmm...

0:27:19 'cause it actually drives questions that you wouldn't otherwise be pushing on. Yeah. Because I think there's, there's an easy...

0:27:28 There's a way, I think, that we all, when we're starting these companies out, it's easy to get theoretical about stuff. You have your drawings and you have even your, like, basic prototypes.

0:27:37 But until you've actually reduced something into a pre-clinical model, it doesn't, it really doesn't matter. Yeah. You know? Yeah.

0:27:44 I remember when we were, we were debating on whether or not to do a first human feasibility study with our peripheral system at Fast Wave 'cause FDA wasn't re- was, was gonna require it.

0:27:52 But we quite honestly struggled with that decision. Do we allocate the resources to do it? And I remember having a conversation with, I, I won't name his name. But he- you would, you probably know him personally, right?

0:27:59 Very well-respected VC in our space for quite some time. And he's like, "Look, I think you guys should really do that. It... You'll-- There's always gonna be unexpected things that you learn."

0:28:06 And sure enough, he was right. You know what I mean? But leading up to that decision and then executing against it, like, there's a-- everyone-- there's always the level of concern.

0:28:13 And so I guess maybe the take home message for those listening is that's normal, right?

0:28:15 You're gonna, you're gonna encounter, right, people that are, feel nervous about it, and oftentimes you just need to push through it and set some sort of date to get into, into, whether it's a cadaver lab, an animal lab, what have you.

0:28:24 Right. It's never gonna, it's never gonna feel probably great, especially in the early [laughs] stages.

0:28:28 With that said, let's talk a little bit about the kind of the, the clinical pathway and whether or not you wanna address it specifically with Tioga and kind of the, the first in human work there, or just previous startups.

0:28:38 When you think about going from even choosing, right, uh, locations for first in human and then building out that clinical roadmap, are there a few key learnings or lessons learned over, over time that kind of, that come to mind when you think about building, building out that, that sort of, that function within a startup?

0:28:52 Yeah. For us, for a mitral valve company, you actually need to have a, a center that is, one is, sees a lot of these patients. So not all...

0:29:02 It takes a relatively advanced medical system to be able to see mitral valve regurgitation patients because while the incidence is high and prevalence is high across the world, if they don't have any therapies at all, they're actually not even coming into [laughs] the physician's office.

0:29:17 Hmm. So you do need a site, I think, that is gonna feed you a lot of patients. So that's number one. And number two is you wanna make sure that they can take care of the patients afterwards.

0:29:26 And, and we worry about this a lot with, with a TMVR company, which is an implant-based company. But implanting the valve is only the first step.

0:29:33 Then they're your patient for life, and making sure that they're followed up correctly and their medications are correct, that's really important.

0:29:40 The third thing I think would be, uh, really good CRO support because you're not gonna be able to do most of these things on your own, uh, even if you have a really good, uh, reg clin advisor.

0:29:52 There's just a lot of, there's a lot of local knowledge that you need to get into most of these locations. And then I think four is you wanna make sure that your locations are credible enough and accepted by your KOLs.

0:30:05 Like, I, I don't think you wanna go into geographies that, that your KOLs would necessarily scratch their head or whatever. [laughs] There has to be a really...

0:30:14 So I think we've selected all of our sites with th- those things in mind. Yeah.

0:30:18 The kind of the, the first point and the latter point especially resonate with me, especially the first point around en- enrollment, 'cause, like, sometimes there could be, like, an attractive geography, right?

0:30:26 That is a very fast path into, into a local IRB approval, and it sounds great- But then once you have approval to actually do cases, like, m- the patients just aren't there, right?

0:30:36 [laughs] Like, enrollment becomes really difficult, and then this feasibility study ends up being really lengthy because of that one issue, right?

0:30:43 You just can't find the patients or, or maybe the site doesn't have an infrastructure to really support the proper screening, et cetera. So that's a really, that's a really good point.

0:30:50 And then the latter, the latter thing that you mentioned around just credibility, right? Um, if you're using this to...

0:30:56 whether it's to garner other support from KOLs, investor support, et cetera, and you're going into a geography that no one's ever been to before, like, just know that's, that's gonna...

0:31:05 people are gonna question that, right? And so, yeah, that's a really good point. And then just out of curiosity, this is probably in the public domain, I imagine, but your first...

0:31:11 your sites or your first in ca- were they in, in Europe or were they- In Republic of Georgia as well as Paraguay. Ah, got it. Got it. Very good. Cool. Awesome. Sounds good.

0:31:20 Let's talk a little bit about capital raising, which you've done a fair amount of over the years, and I think you raised, I think, roughly over 70 million now, maybe something like that for Tioga.

0:31:28 I think your, what, your Series C was maybe a year ago or so, maybe two years ago. Yeah, a year and a half. Yeah. A year and a half ago now.

0:31:34 So you've been around the block when it comes to fundraising, and so how you approach fundraising now, I'm sure, like, is different than it was maybe 10 years ago.

0:31:42 And so when you think about key things that you really wish maybe you knew back, back then that now, are there, like, one or two things that kind of come to mind that are especially, like, critical for anyone that's new to the fundraising game?

0:31:53 Yeah. I, I think number one is we're really lucky and fortunate at ShifaMed to be, to be all part of the whole ShifaMed infrastructure here because of...

0:32:02 we have a group of really captive investors, inside investors- Mm-hmm... that have really supported all the companies, including Tioga, over the last few years and everything.

0:32:11 I think, so that's number one is maybe make sure that you're in a really good ecosystem. [laughs] Mm-hmm. It's really helpful. But I also think that there's always a question of trying to raise outside capital.

0:32:22 I think trying to...

0:32:23 probably there's a few, uh, firms that like to do early stage deals, and I think I would work with those firms very early on, and 'cause a lot of those firms, they don't really like to get involved at Series B or C.

0:32:35 They like Seed or Series A.

0:32:37 So make sure you get involved with them and make sure that your story is really crisp and that it's very compelling and that you actually can achieve an exit within a relatively, um, defined point in time.

0:32:49 Venture firms, as we all know, is they have 10-year horizons and, and basically if they make an investment, it's starting-- things are getting old by the six to seven-year point.

0:32:58 And so you really wanna be at a point where you can make that argument, and I think that's probably more than anything. And I-- raising capital is harder than it was 20 years ago, let's face it. Mm-hmm.

0:33:08 There's a lot of the traditional VCs that have maybe not even left VC, but they've pivoted more strongly to tech only, and it's left us with a smaller share of the overall VC pie.

0:33:20 Even though I think the nu-number of dollars invested, I believe, is pretty much on par with what it was. So I, I don't necessarily have any critical tidbits other than just be resolute and have a great story.

0:33:32 [laughs] Yeah. Yeah. It sounds simple or straightforward, but, like- Yeah... much harder to really hone and, and, and practice.

0:33:38 I wanna touch on, on, on, on ShifaMed 'cause it's a really impressive sort of collection of, of companies, right? I've had, had Brian with Adona on a couple months ago.

0:33:45 Then, then I mentioned, uh, Nitin with Superda on and then n-now you. It's really impressive kind of group of companies, really impressive entrepreneurs, to be honest.

0:33:51 And so when you think about the importance of being around that, that group as it relates to fundraising, that, that's probably something I, I underappreciated five years ago is that, like, how critical that really is.

0:34:03 It really de-risks a lot of... just de-risk, plain and simple, right? A, a, a lot of early stage investment.

0:34:09 So you having been with so many startups could probably pick and choose and go off and do your own thing and not be part of kind of the ShifaMed family, but clearly you've made that decision. So is that...

0:34:19 I would presume that's pretty critical to be a part of that. It make, it makes fundraising... N-fundraising is not never easy, but it does certainly help a lot to be surrounded by that type of- Yeah.

0:34:27 There's really only a few places really in the world that do what ShifaMed does. ShifaMed's certainly one of the premier, uh, incubators.

0:34:35 I think one of the things that's special about it is that Amr is really committed to the med tech space, and he's willing to, to start these companies and get these companies seeded before they have...

0:34:47 That's the way the ShifaMed model works, is that Amr seeds them for a year or so, and then we bring in outside investors or our internal investors to, to continue them on.

0:34:56 And that's an ecosystem that is really important and, and it's great to be around because- Mm-hmm... otherwise, back to what you're saying, I-- it's really hard to fa- raise that seed capital. Mm-hmm.

0:35:06 And so this is a-- ShifaMed is a place where you can do that, and you can actually get a project going and get it to Series A, and Amr's done it time and time again from seed to Series A, and I think that, to me, that-that's why I'm here.

0:35:19 That's why I think it's... 'cause raising money is one of the hardest things that we do as CEOs, right? Oh, yeah. If not the hardest thing. [laughs] Yep.

0:35:28 It, it makes you sometimes feel like almost like a wealth manager where you're trying to like- Yeah. [laughs]... trying to present the- Yeah... the opportunity in that, in that sort, in that sort of framework.

0:35:34 But that, that's so s-crucial.

0:35:35 I guess I bring that up because, and I mentioned this, I, 'cause I underappreciated it earlier in my career, is that you may be giving up a little bit economically, but the cold truth is that there just isn't a lot of places where you can go to get seed capital to take some of these risks early on.

0:35:48 It's just- Yeah... it's-- you need to get your thing to a certain point r- to attract the kind of the next sort of wave of, of investors and that early stage money is incredibly difficult to find. And yeah. Yeah.

0:35:59 And it's also really great, the second part of ShifaMed is just once you have the company going, the back office, uh, functions are really f- uh, concentrated at ShifaMed, whether it be finance, accounting, HR, et cetera.

0:36:11 So we don't have to replicate those, those functions, and they're all standardized. And so that- That does make things easier as well. Yeah. And we're all close to one another.

0:36:19 If we have a question, it's pretty easy to walk across the street and just talk to somebody. Oh, yeah, that can be pretty, pretty valuable, right?

0:36:26 To, to be so closely connected both- And the ShifaMed, uh, senior staff team gets together once a week.

0:36:31 All the CEOs get together and we talk about what's working for the companies, where they are, what the key strategic messages are. So it's great at that level as well. Yeah.

0:36:39 And Shi- ShifaMed, if you're new to ShifaMed, it's, uh, S-H-I-F-A Med.com, shifamed.com. We'll link to the full write-up on MedSider of course.

0:36:46 But highly encourage everyone who's new to, new to this, definitely a cool kind of ecosystem there that, uh, Amr has built out, and really impressive group of people, like from, I mentioned Brian and Nitin, and now you.

0:36:55 There's probably a couple other ShifaMed folks that I need to have on the program. Really, uh, everyone's really impressive. And all kind of bring a different degree of experience, right?

0:37:01 Which I think is probably, I would imagine, is probably pretty valuable in those, in those, those weekly, uh, kind of regroup. With that said, we touched on exits, right, earlier on.

0:37:09 Looking at strategic profiles or who, who... like a- and trying to answer the question, who are the natural acquirers, right, for this sort of technology?

0:37:14 Knowing almost undoubtedly the, the most likely exit or le- liquidity event for a med tech startup, I, I think IPOs maybe the window will open up back again at some point, but this, this, they're really rare, right?

0:37:24 So an M&A event is usually the path forward.

0:37:26 Uh, what's your best advice for engaging with strategics, whether it's in the form of, you know, investment, right, onto the, in- into the cap table, or just building relationships with in, in, in general?

0:37:36 Do you typically like to do that very early on in the process, or do you like to wait to a certain, to a certain milestone to begin to, to have some of those relationships or, or bu- build some of those, th- that, that awareness?

0:37:46 I would try to do it as early as possible.

0:37:48 That's what we've done, and I think that's one of the things that we all do, we do across the board at ShifaMed, is we, we're always talking to the strategics, trying to get a sense for where they are and where they will be, and get an idea of what their pain points are.

0:37:59 They're another... just like physicians are, are KOLs and they're our customers, our, the strategics really are our customers as well. It's reality. Let's just face it.

0:38:08 And we have to understand what's important for them. So I, I would do it as early as possible because you'll get a perspective that, you,

0:38:16 you, you may realize that may be true today and it may not be true in three years, but, but you, I think it's an important perspective to have early on. Yeah, no doubt.

0:38:24 And I, I'm sure you probably are around other founders or entrepreneurs are just hesitant, right, to engage with strategics or have these conversations because they're afraid of maybe their technology being stolen or their idea being stolen.

0:38:36 And it's, that's so rare. That doesn't...

0:38:37 These things are, are very hard to build and to get to a, a clinical milestone, first in human clinical milestone, especially in a space like, like you're operating in, it's, that's shouldn't be a concern, right?

0:38:46 Starting to form some of these relationships early on is really critical. I wanna leave a few minutes for this, the, the rapid-fire portion of the interview, but let's touch quickly on IP.

0:38:52 You've got a, you've got a lot of patents under your belt. Has your opinion changed on IP over the years, especially with, with a lot of kind of the, even the more recent changes with respect to the PTAB?

0:39:02 Like any, any sort of counterintuitive thoughts or do you remain- My, um- Yeah... my semi-controversial thoughts is I think our IP counsel is probably gonna cringe at this, but I, I would say patents are overrated. Yeah.

0:39:15 And, and what I mean by that, I don't mean that they're unimportant, but I think the most important thing that we have to do when you're starting a company is solve the problem first.

0:39:23 And yeah, you can take a, a, a high-level look at IP because you wanna make sure you're not going into an area that you can't really innovate yourself out of, but don't over, don't spend over too much early on.

0:39:36 Just focus on solving the problem. And if you solve the problem, more often than not, I think the IP will work itself out.

0:39:42 Uh, you may have to make some modifications, you may have to change some things, but I think it's really easy to get overly in- as an inventor and, "Oh, I'm an inventor with all these patents and everything."

0:39:53 It doesn't matter, actually. [laughs] Like these patents, they're really important, right? Don't, again, don't get me wrong.

0:39:58 You have to have patents and you have to protect your invention, and you wanna make sure that you have freedom to operate. But the more important thing is to actually have a solution that works.

0:40:07 And I guess that's what, that's really what I'm saying more than anything else, is that don't let the obsession around IP overwhelm your ability to solve the problems.

0:40:17 And again, this was another thing that Tom Foley always mentioned years ago, is that he's, he, he actually told his engineers early on, "Don't even look at patents.

0:40:25 Just solve the problem and, and we'll worry about the IP later." And I think there's a little bit of truth to that because- Hmm...

0:40:32 you, you can get constrained a little bit if you spend too much time trying to understand patents. You wanna be careful with it. Yeah. So that's, I guess that's my little bit of my controversial take on IP.

0:40:43 That's the breaking news part of this interview, right? [laughs] Is Mike Tadeen's take on IP. [laughs] And then j- joking aside, like I couldn't agree more, right? I think you phrased it really well.

0:40:49 It's IP is important, but it shouldn't be the dominant focus early on.

0:40:52 Like solving the problem and most likely solving these problems does come with its own, like i- its own technical, pretty significant technical lift, right?

0:41:00 So if you can get over that hurdle, u- usually you could find a, a path forward with, with- Yeah... IP.

0:41:05 But- Yeah, because usually, like when you solve these problems, you have to solve them in a way, y- just from a marketing standpoint, you have to solve them in a way, in a clinical need standpoint, you have to solve them the way that no one else has solved them before.

0:41:15 Mm-hmm. So when you do that, you usually end up having some pretty unique stuff that you, that you have.

0:41:20 And yeah, yeah, you may have to make some changes for freedom to operate, but you can worry about that once you've solved the problem for the most part.

0:41:26 And, and I'm sure you've probably seen some of the, uh, the, the tweets from Elon where he's, "Patents are for the weak." [laughs] And that's obviously like a click ba- a clickbaity type of phrase.

0:41:33 But there, there's, there's a certain amount of truth to it, right? Um- Yeah... even though it's, it's, it's a bit of an extreme statement, there's a certain amount of truth, right?

0:41:39 Is the hardest thing is like the, the technical, like requirements to build this solution, right? Um, not necessarily the IP around it, right? That doesn't necessarily mean that IP, to your point, is, is not important.

0:41:49 It is, but shouldn't be the, the dominant point, the dominant part of the, the conversation early on. Cool. So, uh, with that said, let's get to the rapid-fire p- uh, portion of this interview.

0:41:56 Again, uh, tiogacardiovascular.com is the website, T-I-O-G-A cardiovascular.com. We'll link to it in the full write-up on MedSider, uh, as well as the show notes in the podcast player that you're listening to as well.

0:42:07 So with that said, questions are rapid-fire in nature. If you wanna expound a little bit on your answers, that's totally fine, Mike. But for the, the first one, let's fast-forward to late 2025.

0:42:15 What are you-- what's the, like the single most thing that you're excited about at, at Tioga looking a year out? Yeah, I'm really excited about the clinical phase that we're entering.

0:42:23 So we have, as I mentioned, we have three patients now. By the end of next year, we'll have probably 15 or 20 patients. We will be submitting a, a, a EFS IDE to FDA next year.

0:42:34 If things go well, hopefully we'll be in the US by the end of next year, by the middle to end of next year. So that's super exciting to me to be, to s- continue to move the, the clinical program along. Yeah.

0:42:44 There's, there's no need for a, a second home in, in Paraguay or maybe Eastern Europe, right? [laughs] If we can get [laughs] we can get through that network quickly and get into your IDE stuff. Yeah.

0:42:51 Certainly fun times, especially considering s- we talked about this earlier. You started Tioga five-ish years ago or so. Yeah. It just takes, these startups just take in med tech.

0:42:59 It's, it's a hard thing, but it's the fun thing too, right? They take so long to get to this point. Def- definitely exciting times for sure.

0:43:04 Since, since co-founding the company a half-decade ago, what's the most surprising thing that you've learned? Oh, boy. Yeah, I was looking at the questions before- [laughs]...

0:43:13 and I was trying to figure out exactly how I should answer this one. I, I think I knew this would be hard. I've even been, I've been humbled at how hard it has been- Mm... to be quite honest.

0:43:22 Again, I was going into this not being unrealistic or naive t- with it. I, we knew that my tool would be hard, but it's just, it's taken way hard. W- uh, just taken a lot more.

0:43:31 And part of it has been working through COVID. Mm. So I think that's, I don't know, that might be the most surprising thing that I've learned. Yeah. Yeah. Yeah. No, that, that speaks volumes, right? Yeah.

0:43:40 'Cause you've had a ton of experience at various startups. Yeah. And all startups, even if there's a relatively low technical hurdle, like, they're all hard, right? Sure. But especially operating in that space.

0:43:49 So I think, I know may- maybe if you're listening to this and you're like, "That doesn't stand out," I just wanna reiterate, like, these things are hard. They're fun, but they're really hard. So don't worry about...

0:43:56 Typically, you don't have to worry about people stealing [laughs] your ideas.

0:43:59 Like, these things are really hard to get to even a, a point where you're in, in, in patients now, which is, which is pretty, pretty cool point. All right.

0:44:05 Let's presume we're in, maybe we're, we're, maybe, w- maybe Amar hosted, hosted a, a, a, a dinner, right, for a bunch of med tech entrepreneurs, and you just got done maybe presenting on the Tioga story or your personal journey.

0:44:16 If there's one lesson that you'd want to leave, like, the, the younger crowd of med tech entrepreneurs with, what would that be? Yeah.

0:44:25 This is also one that I similarly was struggling with trying to find z- this jewel of a- [laughs]... of advice, et cetera. It's, and I was thinking about this in context of, of, of me.

0:44:37 If, if I was doing what I was doing now 20 or 30 years ago, like, how would I take it in?

0:44:43 And I personally, I think I would've had a hard time doing what I'm doing now 30 years ago, and primarily because there's, the amount of pressure and the ups and downs are so dramatic that it's extremely difficult on a day-to-day basis to maintain your sanity [laughs] sometimes.

0:44:58 [laughs] I think this is true for any CEO, right? 'Cause you have financing woes, you have patient woes, you, uh, patient enrollment ro- woes. You have a lot of different things that you're trying to manage.

0:45:07 And I think the, what you start to realize or what I've really started to realize is that you've gotta, you've gotta focus on the process. And more than anything else, sometimes when you, when you get

0:45:20 overly consumed about the outcome, whatever, from two years, three years from now, it becomes overwhelming. But you really are only trying to do...

0:45:29 You gotta think about, you gotta divide your, your year into months and then months into weeks and then days, and really just focus on what you're gonna do, uh, that's right in front of you.

0:45:39 And again, I know this sounds silly or basic. Sitting down the night before and really deciding what you're gonna do the following day and, and, and don't even do anything at the time.

0:45:48 Just really try to focus and try to get into a, a little bit of a zen mode and- Hmm... think about what are the most impactful things you can do in the next day.

0:45:56 Those are the c- that's how you're gonna eventually move the needle forward. To me, that's what's really been helpful, I- Yeah... I think ultimately.

0:46:02 It reminds me of, I can't remember if it was a blog post or maybe in one of Tim Ferriss's books, like very early on when he was, like, coming into his notoriety.

0:46:09 He mentioned that one, that something fairly similar, right? That's often the advice that he gives to other entrepreneurs is like, these things are so hard and it's so up and down. You gotta find an outlet- Yeah...

0:46:17 basically or, like, some sort of, like, you, you mentioned a process, but some- something that allows you to maintain some sort of cadence- Yeah...

0:46:24 or some sort of levelness for lack of a better description to [laughs] Right... to life 'cause these, it's, these things are hard.

0:46:29 Don't get me wrong, like, I- it'd be hard for me to ever do a startup outside of some sort of health-related startup 'cause they are really rewarding.

0:46:34 The problems, the, the, the major problems that you're solving, right, with your device, and hopefully it, it eventually gets into patients here in, in, in the US and a- a- approved, et cetera.

0:46:43 It's really cool and rewarding, but [laughs] it's, uh, I always like to use this phrase, it's like build, it's like playing a video game on hard mode all the time, right? It's like [laughs] you're- Yeah...

0:46:51 you're on level 10 all the time, uh, in, in med tech. So, uh, I'm glad you brought that up. Yeah. Just on, on that front, I was, uh, I was really, I've been reading a lot of, of stoic philosophy recently.

0:47:02 I've started reading, like, Epictetus and stuff like that- Hmm...

0:47:04 and Marcus Aurelius, and it's actually really helpful [laughs] as a, as a med tech CEO 'cause you have to really focus on the stuff that you can move, and there's a lot of things that you can move, but there's certain things that you can't.

0:47:15 Did you get into the stoic stuff through Ryan Holiday at all? Or did you just- No, I- You just went straight to the source. You're like- I, yeah, I went straight to the source. [laughs] Yeah.

0:47:21 But I've been reading that, like, on the plane slowly. It's a little, it's somewhat dense reading, but it's, it's interesting. Yeah, yeah. It's a good framework for sure. All right, last question.

0:47:30 Take us back to maybe your late 20s, your first maybe getting into kind of pharma/med tech, mid to late 20s. Anything you'd whisper at the younger, in the ears of the young- your, the younger version of yourself? Yeah.

0:47:40 It'll be all right. [laughs] It'll turn out fine. Yeah. Keep, keep working hard. It'll turn out fine. Uh, like, literally that, uh, the sense of hope I think is really important, right? It is. It is. Yeah. Yeah.

0:47:51 It's easy to get caught up in, whether it's that milestone that you're chasing or that outcome and just get so anxious about it. But, uh, yeah, it's really, really good words of advice.

0:48:00 I think, I think anyone listening shouldn't take those lightly considering you've been, had, you've had a, a lot of startup experience, right? It means especially important a- advice.

0:48:07 So with that said, uh, Mike, I can't thank you enough for, for coming on the program. It's been a fun conversation.

0:48:11 TiogaCardiovascular.com is the website, T-I-O-G-A Cardiovascular.com, part of the ShifaMed family of companies.

0:48:20 I'll have you hold on the line, Mike, but thanks again for carving out a little bit of time to tell us not only about Tioga, but your kinda journey in, in med tech as well. Really appreciate it, Scott. Really enjoyed it.

0:48:28 Thank you so much. And for everyone listening, thanks as always for your attention. You've gotten this far. Until the next episode of Medsider Goes Live, everyone, take care. [upbeat music] Hey, it's Scott again.

0:48:36 One quick thing before you go. You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups. But here's the thing.

0:48:44 I'd be super grateful if you could help me reach even more ambitious doers who share our passion.

0:48:48 So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with Medsider, please take a moment to leave us a review. It's super easy.

0:48:57 Just open your Apple Podcasts app or the podcast app of your choice, search for our show, and scroll down to the ratings and review section.

0:49:03 Leave your honest thoughts and hit that five-star rating if you think we're worthy.

0:49:06 Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.

0:49:15 As always, thanks for being a part of our journey and for helping Medsider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews.

0:49:22 Stay tuned for another informative episode coming at you soon. [upbeat music]